Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033

Charles D. Blanke, Cathryn Rankin, George D. Demetri, Christopher W. Ryan, Margaret Von Mehren, Robert S. Benjamin, A. Kevin Raymond, Vivien H.C. Bramwell, Laurence H. Baker, Robert G. Maki, Michael Tanaka, J. Randolph Hecht, Michael C. Heinrich, Christopher D.M. Fletcher, John J. Crowley, Ernest C. Borden

Research output: Contribution to journal › Article › peer-review

906 Scopus citations

Fingerprint

Dive into the research topics of 'Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033'. Together they form a unique fingerprint.

Medicine & Life Sciences